These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 31025833)

  • 21. Changes of plasma proteins after immunoadsorption using Ig-Adsopak columns in patients with myasthenia gravis.
    Pták J
    Transfus Apher Sci; 2004 Apr; 30(2):125-9. PubMed ID: 15062750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fibrinogen reconstitution after therapeutic apheresis: Comparison of double-filtration plasmapheresis, plasma exchange, and immunoadsorption.
    Jouve T; Marlu R; Naciri Bennani H; Noble J; Chevallier E; Motte L; Imerzoukene F; Malvezzi P; Rostaing L
    J Clin Apher; 2021 Aug; 36(4):574-583. PubMed ID: 33783856
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The use of therapeutic apheresis in neurological diseases and comparison between plasma exchange and immunoadsorption].
    Loschiavo C; Grecò M; Polo A; Del Colle R
    G Ital Nefrol; 2015; 32(1):. PubMed ID: 25774587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Specific removal of anti-acetylcholine receptor antibodies in patients with myasthenia gravis.
    Takamori M; Ide Y
    Transfus Sci; 1996 Sep; 17(3):445-53. PubMed ID: 10163553
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of myasthenia gravis by immunoadsorption of plasma.
    Grob D; Simpson D; Mitsumoto H; Hoch B; Mokhtarian F; Bender A; Greenberg M; Koo A; Nakayama S
    Neurology; 1995 Feb; 45(2):338-44. PubMed ID: 7854536
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elimination of IgG subclasses of anti-acetylcholine receptor antibodies in myasthenic plasma by immunoadsorption to protein A.
    Szpirt W; Somnier F; Nielsen FC; Rødgaard A
    Life Support Syst; 1985; 3 Suppl 1():351-5. PubMed ID: 3916613
    [No Abstract]   [Full Text] [Related]  

  • 27. Selective plasma exchange.
    Ohkubo A; Okado T
    Transfus Apher Sci; 2017 Oct; 56(5):657-660. PubMed ID: 28939369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic apheresis in myasthenia gravis.
    Batocchi AP; Evoli A; Di Schino C; Tonali P
    Ther Apher; 2000 Aug; 4(4):275-9. PubMed ID: 10975473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunoadsorption apheresis versus intravenous immunoglobulin therapy for exacerbation of myasthenia gravis.
    Yasuda M; Uzawa A; Ozawa Y; Kojima Y; Onishi Y; Akamine H; Kuwabara S
    Scand J Immunol; 2022 Feb; 95(2):e13122. PubMed ID: 34796975
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical evaluation of a staphylococcal protein A immunoadsorption system in the treatment of myasthenia gravis patients.
    Benny WB; Sutton DM; Oger J; Bril V; McAteer MJ; Rock G
    Transfusion; 1999 Jul; 39(7):682-7. PubMed ID: 10413274
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ability to remove immunoglobulins and anti-ganglioside antibodies by plasma exchange, double-filtration plasmapheresis and immunoadsorption.
    Tagawa Y; Yuki N; Hirata K
    J Neurol Sci; 1998 Apr; 157(1):90-5. PubMed ID: 9600682
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of refractory myasthenia gravis by double-filtration plasmapheresis and rituximab: A case series of nine patients and literature review.
    Bennani HN; Lagrange E; Noble J; Malvezzi P; Motte L; Chevallier E; Rostaing L; Jouve T
    J Clin Apher; 2021 Jun; 36(3):348-363. PubMed ID: 33349954
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts.
    Guptill JT; Sanders DB; Evoli A
    Muscle Nerve; 2011 Jul; 44(1):36-40. PubMed ID: 21674519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunoadsorption in myasthenia gravis based on specific ligands mimicking the immunogenic sites of the acetylcholine receptor.
    Takamori M; Maruta T
    Ther Apher; 2001 Oct; 5(5):340-50. PubMed ID: 11778918
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Soluble adhesion molecules and cytokines in patients with myasthenia gravis treated by plasma exchange.
    Tesar V; Jelínková E; Jirsa M; Bakosová M; Pitha P; Chábová V
    Blood Purif; 2000; 18(2):115-20. PubMed ID: 10838470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective plasma exchange can reduce auto-antibodies in patients with bullous pemphigoid without affecting factor XIII and fibrinogen.
    Nasu K; Hanafusa N; Nangaku M
    J Clin Apher; 2017 Dec; 32(6):589-591. PubMed ID: 27709645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Removal kinetics of antibodies against glutamic acid decarboxylase by various plasmapheresis modalities in the treatment of neurological disorders.
    Ohkubo A; Okado T; Kurashima N; Maeda T; Miyamoto S; Nakamura A; Seshima H; Iimori S; Sohara E; Uchida S; Rai T
    Ther Apher Dial; 2014 Jun; 18(3):231-7. PubMed ID: 24965288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tryptophan-immobilized column-based immunoadsorption as the choice method for plasmapheresis in Guillain-Barré syndrome.
    Okamiya S; Ogino M; Ogino Y; Irie S; Kanazawa N; Saito T; Sakai F
    Ther Apher Dial; 2004 Jun; 8(3):248-53. PubMed ID: 15154879
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Postoperative myasthenic crisis successfully treated with immunoadsorption therapy.
    Ishizeki J; Nishikawa K; Kunimoto F; Goto F
    J Anesth; 2005; 19(4):320-2. PubMed ID: 16261471
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Removal Dynamics of Autoantibodies, Immunoglobulins, and Coagulation Factors by Selective Plasma Exchange on Three Consecutive Days.
    Miyamoto S; Ohkubo A; Seshima H; Yamamoto H; Itagaki A; Maeda T; Kurashima N; Mori T; Iimori S; Naito S; Sohara E; Rai T; Uchida S; Okado T
    Ther Apher Dial; 2018 Jun; 22(3):255-260. PubMed ID: 29781127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.